A PHASE 2/3 STUDY TO CHARACTERIZE AND EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF HU 14.18K322A TREATMENT GIVEN IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NEUROBLASTOMA

Registry ID

EPG-HU1418-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

RENAISSANCE PHARMA LTD

Start date

2026-08-07

Last update

2026-04-10

Conditions

• NEUROBLASTOMA

Related clinical trials

• A PHASE 3 STUDY OF DINUTUXIMAB ADDED TO INTENSIVE MULTIMODAL THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
• A PHASE II STUDY OF NAXITAMAB ADDED TO INDUCTION THERAPY FOR SUBJECTS WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
• PILOT STUDY OF 68GA-DOTATATE PET/CT AND 123I-MIBG SCINTIGRAPHY IMAGING OF NEUROBLASTOMA
• PHASE II TRIAL OF EFLORNITHINE (DFMO) AND ETOPOSIDE FOR RELAPSED/REFRACTORY NEUROBLASTOMA
• PEDS-PLAN – PEDIATRIC PRECISION LABORATORY ADVANCED: A STUDY USING MOLECULAR GUIDED THERAPY WITH INDUCTION CHEMOTHERAPY FOLLOWED BY A RANDOMIZED CONTROLLED TRIAL OF STANDARD IMMUNOTHERAPY WITH OR WITHOUT DFMO FOLLOWED BY DFMO MAINTENANCE FOR SUBJECTS WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
• A PHASE 3 STUDY OF 131 I-METAIODOBENZYLGUANIDINE (131I-MIBG) OR CRIZOTINIB ADDED TO INTENSIVE THERAPY FOR CHILDREN WITH NEWLY DISAGNOSED HIGH-RISK NEUROBLASTOMA (NBL) (IND# 134379)

View on source registry